These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 39214097)

  • 1. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8
    Wang K; Coutifaris P; Brocks D; Wang G; Azar T; Solis S; Nandi A; Anderson S; Han N; Manne S; Kiner E; Sachar C; Lucas M; George S; Yan PK; Kier MW; Laughlin AI; Kothari S; Giles J; Mathew D; Ghinnagow R; Alanio C; Flowers A; Xu W; Tenney DJ; Xu X; Amaravadi RK; Karakousis GC; Schuchter LM; Buggert M; Oldridge D; Minn AJ; Blank C; Weber JS; Mitchell TC; Farwell MD; Herati RS; Huang AC
    Cancer Cell; 2024 Sep; 42(9):1582-1597.e10. PubMed ID: 39214097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response.
    Gangaev A; Rozeman EA; Rohaan MW; Isaeva OI; Philips D; Patiwael S; van den Berg JH; Ribas A; Schadendorf D; Schilling B; Schumacher TN; Blank CU; Haanen JBAG; Kvistborg P
    Proc Natl Acad Sci U S A; 2021 Oct; 118(43):. PubMed ID: 34670835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
    Wei SC; Levine JH; Cogdill AP; Zhao Y; Anang NAS; Andrews MC; Sharma P; Wang J; Wargo JA; Pe'er D; Allison JP
    Cell; 2017 Sep; 170(6):1120-1133.e17. PubMed ID: 28803728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
    Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
    Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing clonal changes in T cells over time following immunotherapy is a breeze with Cyclone.
    Cillo AR; Kirkwood JM
    Cancer Cell; 2024 Sep; 42(9):1491-1493. PubMed ID: 39255774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade.
    Okoye IS; Xu L; Walker J; Elahi S
    Cancer Immunol Immunother; 2020 Aug; 69(8):1423-1436. PubMed ID: 32246174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells.
    Viramontes KM; Neubert EN; DeRogatis JM; Tinoco R
    Front Immunol; 2022; 13():869768. PubMed ID: 35774790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
    Levine LS; Mahuron KM; Tsai KK; Wu C; Mattis DM; Pauli ML; Oglesby A; Lee JC; Spitzer MH; Krummel MF; Algazi AP; Rosenblum MD; Alvarado M; Daud AI
    Ann Surg Oncol; 2020 Oct; 27(11):4122-4130. PubMed ID: 32488521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients.
    Subrahmanyam PB; Dong Z; Gusenleitner D; Giobbie-Hurder A; Severgnini M; Zhou J; Manos M; Eastman LM; Maecker HT; Hodi FS
    J Immunother Cancer; 2018 Mar; 6(1):18. PubMed ID: 29510697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade.
    Principe N; Phung AL; Stevens KLP; Elaskalani O; Wylie B; Tilsed CM; Sheikh F; Orozco Morales ML; Kidman J; Marcq E; Fisher SA; Nowak AK; McDonnell AM; Lesterhuis WJ; Chee J
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39343508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral CD8
    Fairfax BP; Taylor CA; Watson RA; Nassiri I; Danielli S; Fang H; Mahé EA; Cooper R; Woodcock V; Traill Z; Al-Mossawi MH; Knight JC; Klenerman P; Payne M; Middleton MR
    Nat Med; 2020 Feb; 26(2):193-199. PubMed ID: 32042196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
    Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
    Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy.
    Eschweiler S; Clarke J; Ramírez-Suástegui C; Panwar B; Madrigal A; Chee SJ; Karydis I; Woo E; Alzetani A; Elsheikh S; Hanley CJ; Thomas GJ; Friedmann PS; Sanchez-Elsner T; Ay F; Ottensmeier CH; Vijayanand P
    Nat Immunol; 2021 Aug; 22(8):1052-1063. PubMed ID: 34168370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TOX-expressing terminally exhausted tumor-infiltrating CD8
    Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
    Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
    Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
    Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonality of CD4
    Arakawa A; Vollmer S; Tietze J; Galinski A; Heppt MV; Bürdek M; Berking C; Prinz JC
    Front Immunol; 2019; 10():1336. PubMed ID: 31275310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
    Twyman-Saint Victor C; Rech AJ; Maity A; Rengan R; Pauken KE; Stelekati E; Benci JL; Xu B; Dada H; Odorizzi PM; Herati RS; Mansfield KD; Patsch D; Amaravadi RK; Schuchter LM; Ishwaran H; Mick R; Pryma DA; Xu X; Feldman MD; Gangadhar TC; Hahn SM; Wherry EJ; Vonderheide RH; Minn AJ
    Nature; 2015 Apr; 520(7547):373-7. PubMed ID: 25754329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion study.
    Bishnoi S; Kotasek D; Aghmesheh M; Yau T; Cosman R; Prawira A; Moore M; Chan SL; Mant A; Eek R; Zielinski R; Su R; Pan Z; Ma Y; Li F; Li P; Tse AN
    Cancer; 2024 Jun; 130(11):1991-2002. PubMed ID: 38404184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.